Abstract:Background Currently approved CAR-T cells primarily utilize retroviral or lentiviral vectors (LV), posing significant challenges due to their time-consuming and costly nature, and associated safety concerns, including insertional mutagenesis. Consequently, mRNA delivery holds promising prospects in CAR-T cell engineering. AXL represents an ideal target for LV-engineered CAR-T cells in the treatment of various malignancies, including breast, lung, and pancreatic cancer. However, the anti-tumor activity of mRNA-based AXL CAR-T cells remains to be fully elucidated. Methods We developed a novel CAR utilizing a fully humanized AXL-specific antibody. Subsequently, the mRNA encoding AXL-specific CAR was synthesized via in vitro transcription. This mRNA was then transfected into pre-activated T cells through electroporation. The expression levels of mRNA-based CAR were evaluated by flow cytometry. Furthermore, in vitro and in vivo assays were performed to evaluate the antigen-specific cytotoxicity and cytokine release capabilities of mRNA-based AXL CAR-T cells in various tumor cells and in a tumor-bearing mouse model. Results Electroporation of mRNA-encoding AXL CAR minimally affected T cell viability, resulting in high CAR expression over 90%, and this CAR expression persisted for at least three days following electroporation, consistent with observed cytotoxicity against the lung cancer cell line A549. mRNA-based AXL CAR-T cells exhibited dose-dependent cytotoxicity against both A549 and pancreatic cancer cell line Panc-1, achieving a killing rate exceeding 80% at an effector:target ratio of 4:1. Additionally, mRNA-based AXL CAR-T cells specifically secreted high level of cytokines IL-2 and IFN-γ upon interaction with target tumor cells. mRNA-based AXL CAR-T cells exhibited minimal impact on T cell subtypes while demonstrating robust cytotoxicity comparable to LV-engineered CAR-T cells. Additionally, mRNA-based AXL CAR-T cells demonstrated good anti-tumor activity in a subcutaneous lung cancer xenograft model. Conclusions mRNA-based AXL CAR-T cells transiently expressed high levels of CAR, enabling cost-effective large-scale production, and comparable functionality to LV-engineered CAR-T cells within a short time frame, which offers a safe alternative for clinical therapy utilizing LV-engineered CAR-T cells. mRNA-based AXL CAR-T cells have shown promising results in treating solid tumors, including lung cancer and pancreatic cancer, establishing an experimental basis for their potential clinical application in solid tumors.

Remodelling of tumour microenvironment by microwave ablation potentiates immunotherapy of AXL-specific CAR T cells against non-small cell lung cancer

A Chimera Antigen Receptor Containing TLR4 Signaling Domain Enhances CAR-iMACs Polarization and Potency against Solid Tumors

Abstract LB342: Potent Anti-Tumor Activity Demonstrated by Anti-AXL CAR T Cell Therapy and AXL-ADC in Lung Cancer and Breast Cancer Models

Chimeric Antigen Receptor-Modified T Cells Redirected to EphA2 for the Immunotherapy of Non-Small Cell Lung Cancer

Microwave ablation combined with PD‐L1 blockade synergistically promotes Cxcl9‐mediated antitumor immunity

AXL antibody and AXL-ADC mediate antitumor efficacy via targeting AXL in tumor-intrinsic epithelial-mesenchymal transition and tumor-associated M2-like macrophage

Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer

Mrna-Based AXL-targeting Chimeric Antigen Receptor-T Cells Against Solid Tumors

Advancing CAR T-Cell Therapy: Simultaneously Attack Tumor and Immunosuppressive Cells in the Tumor Microenvironment

The CXCL10/CXCR3 Pathway Contributes to the Synergy of Thermal Ablation and PD-1 Blockade Therapy against Tumors

Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy

Chimeric CTLA4-CD28-CD3z T Cells Potentiate Antitumor Activity Against CD80/CD86–Positive B Cell Malignancies

Broadening anticancer spectrum by preprocessing and treatment of T- lymphocytes expressed FcγRI and monoclonal antibodies for refractory cancers

Extracellular Matrix Viscosity Reprogramming by in Situ Au Bioreactor-Boosted Microwavegenetics Disables Tumor Escape in CAR-T Immunotherapy.

Optimized CAR-T therapy based on spatiotemporal changes and chemotactic mechanisms of MDSCs induced by hypofractionated radiotherapy

Remodeling of Tumor Microenvironment by Tumor‐Targeting Nanozymes Enhances Immune Activation of CAR T Cells for Combination Therapy (Small 43/2021)

Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models

Abstract 697: Enhanced tumor control and survival in solid tumor models following combined low dose radiotherapy and T cell therapy

CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors

CXCL10 and IL15 co-expressing chimeric antigen receptor T cells enhance anti-tumor effects in gastric cancer by increasing cytotoxic effector cell accumulation and survival

Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo